查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1412835

肝癌診斷市場：按測試類型和最終用戶分類 - 全球預測 2024-2030

Liver Cancer Diagnostics Market by Test Type (Biopsy, Endoscopy, Imaging), End User (Academic & Research Institutes, Hospitals & Diagnostic Laboratories, Pharmaceutical & CRO Laboratories) - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2023年肝癌診斷市場規模為94.1億美元，2024年達到100.5億美元，預計2030年將達到147.4億美元，複合年成長率為6.62%。

全球肝癌診斷市場

主要市場統計
基準年[2023] 94.1億美元
預測年份 [2024] 100.5億美元
預測年份 [2030] 147.4億美元
複合年成長率（%） 6.62%
肝癌診斷藥物市場-IMG1

FPNV定位矩陣

FPNV定位矩陣對於評估肝癌診斷市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標，以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出資訊的決策。根據評估，供應商被分為四個成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市場佔有率分析

市場佔有率分析是一種綜合工具，可以對肝癌診斷市場供應商的現狀進行深入而深入的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻，以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外，該分析還提供了對該行業競爭特徵的寶貴考察，包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。這種詳細程度的提高使供應商能夠做出更資訊的決策並制定有效的策略，從而在市場上獲得競爭優勢。

該報告對以下幾個方面提供了寶貴的見解：

1-市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2-市場開拓：我們深入研究利潤豐厚的新興市場並分析其在成熟細分市場的滲透率。

3- 市場多元化：提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。

4-競爭力評估與資訊：對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況、製造能力等進行全面評估。

5- 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告解決了以下關鍵問題：

1-肝癌診斷市場的市場規模和預測是多少？

2-肝癌診斷市場預測期間需要考慮投資的產品、細分市場、應用和領域有哪些？

3-肝癌診斷市場的技術趨勢和法律規範是什麼？

4-肝癌診斷市場主要廠商的市場佔有率是多少？

5-進入肝癌診斷藥物市場合適的型態和策略手段是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 全球肝癌發生率增加
      • 肝癌診斷的有利報銷框架
      • 肝癌篩檢項目數量增加
    • 抑制因素
      • 熟練且訓練有素的專業人員數量有限
    • 機會
      • 癌症診斷設備技術進展
      • 專注於開發有效的診斷方法
    • 任務
      • 肝癌診斷藥物的局限性
  • 市場區隔分析
  • 市場趨勢分析
  • 高通膨的累積效應
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 法律規範

第6章按測試類型分類的肝癌診斷藥物市場

  • 切片檢查
  • 內視鏡檢查
  • 影像
  • 臨床檢查
    • 生物標記
      • 酵素和同工酶
      • 生長因子和受體
      • 分子標記
      • 癌胚和糖蛋白抗原
      • 病理性生物標記
    • 驗血

第7章肝癌診斷市場：依最終用戶分類

  • 學術研究所
  • 醫院和診斷實驗室
  • 醫藥及CRO研究院

第8章 北美、南美肝癌診斷藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第9章亞太地區肝癌診斷藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第10章歐洲、中東和非洲肝癌診斷市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第11章競爭形勢

  • FPNV定位矩陣
  • 市場佔有率分析：主要企業
  • 主要企業競爭情境分析

第12章競爭產品組合

  • 主要公司簡介
    • Abbott Laboratories
    • Accuray Incorporated
    • Biocartis NV
    • CR Bard Inc.
    • Elekta AB
    • Epigenomics AG
    • F. Hoffmann-La Roche Ltd.
    • Fujifilm Medical Systems USA, Inc.
    • Illumina, Inc.
    • Koninklijke Philips NV
    • Myriad Genetics, Inc.
    • Qiagen NV
    • Siemens AG
    • Sysmex Corporation
    • Thermo Fisher Scientific, Inc.
  • 主要產品系列

第13章附錄

  • 討論指南
  • 關於許可證和定價
Product Code: MRR-3A2E844FE73E

[186 Pages Report] The Liver Cancer Diagnostics Market size was estimated at USD 9.41 billion in 2023 and expected to reach USD 10.05 billion in 2024, at a CAGR 6.62% to reach USD 14.74 billion by 2030.

Global Liver Cancer Diagnostics Market

KEY MARKET STATISTICS
Base Year [2023] USD 9.41 billion
Estimated Year [2024] USD 10.05 billion
Forecast Year [2030] USD 14.74 billion
CAGR (%) 6.62%
Liver Cancer Diagnostics Market - IMG1

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Liver Cancer Diagnostics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Liver Cancer Diagnostics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Liver Cancer Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Accuray Incorporated, Biocartis NV, C.R. Bard Inc., Elekta AB, Epigenomics AG, F. Hoffmann-La Roche Ltd., Fujifilm Medical Systems U.S.A., Inc., Illumina, Inc., Koninklijke Philips N.V., Myriad Genetics, Inc., Qiagen N.V., Siemens AG, Sysmex Corporation, and Thermo Fisher Scientific, Inc..

Market Segmentation & Coverage

This research report categorizes the Liver Cancer Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Test Type
    • Biopsy
    • Endoscopy
    • Imaging
    • Laboratory tests
      • Biomarkers
        • Enzymes & Isoenzymes
        • Growth Factors & Receptors
        • Molecular Markers
        • Oncofetal & Glycoprotein Antigens
        • Pathological Biomarkers
      • Blood Tests
  • End User
    • Academic & Research Institutes
    • Hospitals & Diagnostic Laboratories
    • Pharmaceutical & CRO Laboratories
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Liver Cancer Diagnostics Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Liver Cancer Diagnostics Market?

3. What are the technology trends and regulatory frameworks in the Liver Cancer Diagnostics Market?

4. What is the market share of the leading vendors in the Liver Cancer Diagnostics Market?

5. Which modes and strategic moves are suitable for entering the Liver Cancer Diagnostics Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Liver Cancer Diagnostics Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing Incidence of liver cancer globally
      • 5.1.1.2. Favorable reimbursement framework for liver cancer diagnosis
      • 5.1.1.3. Growing number of liver cancer screening programs
    • 5.1.2. Restraints
      • 5.1.2.1. Limited skilled and trained professionals
    • 5.1.3. Opportunities
      • 5.1.3.1. Technological advancements in cancer diagnosis equipment
      • 5.1.3.2. Focus on development of effective diagnostics
    • 5.1.4. Challenges
      • 5.1.4.1. Limitations of liver cancer diagnostics
  • 5.2. Market Segmentation Analysis
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework

6. Liver Cancer Diagnostics Market, by Test Type

  • 6.1. Introduction
  • 6.2. Biopsy
  • 6.3. Endoscopy
  • 6.4. Imaging
  • 6.5. Laboratory tests
    • 6.6.1. Biomarkers
      • 6.6.2.1. Enzymes & Isoenzymes
      • 6.6.2.2. Growth Factors & Receptors
      • 6.6.2.3. Molecular Markers
      • 6.6.2.4. Oncofetal & Glycoprotein Antigens
      • 6.6.2.5. Pathological Biomarkers
    • 6.6.2. Blood Tests

7. Liver Cancer Diagnostics Market, by End User

  • 7.1. Introduction
  • 7.2. Academic & Research Institutes
  • 7.3. Hospitals & Diagnostic Laboratories
  • 7.4. Pharmaceutical & CRO Laboratories

8. Americas Liver Cancer Diagnostics Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Liver Cancer Diagnostics Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Liver Cancer Diagnostics Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. FPNV Positioning Matrix
  • 11.2. Market Share Analysis, By Key Player
  • 11.3. Competitive Scenario Analysis, By Key Player

12. Competitive Portfolio

  • 12.1. Key Company Profiles
    • 12.1.1. Abbott Laboratories
    • 12.1.2. Accuray Incorporated
    • 12.1.3. Biocartis NV
    • 12.1.4. C.R. Bard Inc.
    • 12.1.5. Elekta AB
    • 12.1.6. Epigenomics AG
    • 12.1.7. F. Hoffmann-La Roche Ltd.
    • 12.1.8. Fujifilm Medical Systems U.S.A., Inc.
    • 12.1.9. Illumina, Inc.
    • 12.1.10. Koninklijke Philips N.V.
    • 12.1.11. Myriad Genetics, Inc.
    • 12.1.12. Qiagen N.V.
    • 12.1.13. Siemens AG
    • 12.1.14. Sysmex Corporation
    • 12.1.15. Thermo Fisher Scientific, Inc.
  • 12.2. Key Product Portfolio

13. Appendix

  • 13.1. Discussion Guide
  • 13.2. License & Pricing

LIST OF FIGURES

  • FIGURE 1. LIVER CANCER DIAGNOSTICS MARKET RESEARCH PROCESS
  • FIGURE 2. LIVER CANCER DIAGNOSTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. LIVER CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. LIVER CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. LIVER CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. LIVER CANCER DIAGNOSTICS MARKET DYNAMICS
  • FIGURE 7. LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2023 VS 2030 (%)
  • FIGURE 8. LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 10. LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. AMERICAS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 12. AMERICAS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. UNITED STATES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 14. UNITED STATES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. ASIA-PACIFIC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. ASIA-PACIFIC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. LIVER CANCER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023
  • FIGURE 20. LIVER CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

  • TABLE 1. LIVER CANCER DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. LIVER CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 6. LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. LIVER CANCER DIAGNOSTICS MARKET SIZE, BY ENDOSCOPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. LIVER CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 11. LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 13. LIVER CANCER DIAGNOSTICS MARKET SIZE, BY ENZYMES & ISOENZYMES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GROWTH FACTORS & RECEPTORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. LIVER CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR MARKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. LIVER CANCER DIAGNOSTICS MARKET SIZE, BY ONCOFETAL & GLYCOPROTEIN ANTIGENS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PATHOLOGICAL BIOMARKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 20. LIVER CANCER DIAGNOSTICS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. LIVER CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS & DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PHARMACEUTICAL & CRO LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 191. LIVER CANCER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023
  • TABLE 192. LIVER CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 193. LIVER CANCER DIAGNOSTICS MARKET LICENSE & PRICING